PMID- 20538389
OWN - NLM
STAT- MEDLINE
DCOM- 20110915
LR  - 20161018
IS  - 1768-3122 (Electronic)
IS  - 0248-8663 (Linking)
VI  - 32
IP  - 4
DP  - 2011 Apr
TI  - [Bradykinin mediated angioedema].
PG  - 225-31
LID - 10.1016/j.revmed.2009.11.021 [doi]
AB  - Bradykinin angioedema (AE) are characterized by acute recurrent episodes of 
      localized swelling. They are not associated with pruritus or erythema, and are 
      short-lived (24 to 72 hours), disappearing without any sequelae. Corticosteroids 
      are useless. Skin or mucous membranes (upper respiratory and intestinal) could be 
      affected. Bradykinin AE can be secondary to: (1) AE associated with C1 inhibitor 
      deficiency (hereditary or acquired); (2) drug-induced AE (converting enzyme 
      inhibitors...); (3) type III AE type (oestrogen dependant) without C1 inhibitor 
      deficiency. These type III AE can be associated with a gain of function mutation 
      that markedly increases factor XII activity. Prognosis depends on the laryngeal 
      attacks (resulting in 25 % of death in the absence of specific treatment). In 
      case of severe attacks, icatibant (bradykinin receptor antagonist) or C1 
      inhibitor concentrate can be used. In case of frequent attacks, long-term therapy 
      with danazol or tranexamic acid is effective.
CI  - Copyright (c) 2010 Societe nationale francaise de medecine interne (SNFMI). 
      Published by Elsevier SAS. All rights reserved.
FAU - Bouillet, L
AU  - Bouillet L
AD  - Centre de reference sur les angioedemes bradykiniques (CREAK), clinique 
      universitaire de medecine interne, BP 217, 38043 Grenoble cedex 09, France. 
      LBouillet@chu-grenoble.fr
FAU - Boccon-Gibod, I
AU  - Boccon-Gibod I
FAU - Massot, C
AU  - Massot C
LA  - fre
PT  - English Abstract
PT  - Journal Article
TT  - Les angioedemes bradykiniques hereditaires ou acquis.
DEP - 20100609
PL  - France
TA  - Rev Med Interne
JT  - La Revue de medecine interne
JID - 8101383
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Antifibrinolytic Agents)
RN  - 0 (Complement C1 Inhibitor Protein)
RN  - 0 (Complement Inactivating Agents)
RN  - 0 (Estrogen Antagonists)
RN  - 0 (Genetic Markers)
RN  - 0 (Vasodilator Agents)
RN  - S8TIM42R2W (Bradykinin)
SB  - IM
MH  - Angioedema/drug therapy/*genetics/physiopathology
MH  - Angioedemas, Hereditary/genetics
MH  - Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
MH  - Antifibrinolytic Agents/therapeutic use
MH  - Bradykinin/*genetics
MH  - Complement C1 Inhibitor Protein/genetics
MH  - Complement Inactivating Agents/metabolism
MH  - Estrogen Antagonists/therapeutic use
MH  - Genetic Markers/genetics
MH  - Humans
MH  - Prognosis
MH  - Treatment Outcome
MH  - Vasodilator Agents/*metabolism
EDAT- 2010/06/12 06:00
MHDA- 2011/09/16 06:00
CRDT- 2010/06/12 06:00
PHST- 2009/11/13 00:00 [received]
PHST- 2009/11/15 00:00 [accepted]
PHST- 2010/06/12 06:00 [entrez]
PHST- 2010/06/12 06:00 [pubmed]
PHST- 2011/09/16 06:00 [medline]
AID - S0248-8663(10)00744-7 [pii]
AID - 10.1016/j.revmed.2009.11.021 [doi]
PST - ppublish
SO  - Rev Med Interne. 2011 Apr;32(4):225-31. doi: 10.1016/j.revmed.2009.11.021. Epub 
      2010 Jun 9.